Journey Medical Corporation Enters Exclusive License Agreement With Maruho Co., Ltd. For Qbrexza In South Korea And Other Asian Nations; Co. To Receuve $19M Upfront Payment And Is Eligible For Certain Milestones Totaling Up To $45M
Portfolio Pulse from Benzinga Newsdesk
Journey Medical Corporation has entered an exclusive license agreement with Maruho Co., Ltd. for Qbrexza in South Korea and other Asian nations. The company will receive a $19M upfront payment and is eligible for certain milestones totaling up to $45M.
September 06, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Journey Medical Corporation, a subsidiary of Dermira, Inc. (DERM), has entered into a lucrative licensing agreement which could positively impact DERM's revenues.
The news directly pertains to Journey Medical Corporation, a subsidiary of Dermira, Inc. (DERM). The licensing agreement, which includes a significant upfront payment and potential for further milestone payments, could significantly boost DERM's revenues in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100